Retatrutide , a triple-agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, has shown weight loss results exceeding those of current dual-agonists
(PubMed) Secades JJ, Alvarez-Sabin J, Castillo J, et al
Sign up to get science-backed insights, exclusive content, and regular updatesjoining 85,000+ others in Chris Masterjohns community
Claims made by companies in the context of such activities should align with rational medicine use and public health goals
Serious side effects of the prescription medication include pancreatitis, thyroid tumors, gastroparesis (stomach paralysis), and ileus (intestinal blockage)
"Peptides and the pituitary: new insights into GH secretion." Endocrinol Metab Clin North Am